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Pasteurized donor human milk is provided by milk banks to very preterm babies where their
maternal supply is insufficient or unavailable. Donor milk is currently processed by Holder
pasteurization, producing a microbiologically safe product but significantly reducing immu-
noprotective components. Ultraviolet-C (UV-C) irradiation at 254 nm is being investigated
as an alternative treatment method and has been shown to preserve components such as
lactoferrin, lysozyme and secretory IgA considerably better than Holder pasteurization. We
describe the inactivation of cytomegalovirus, a virus commonly excreted into breast milk,
using UV-C irradiation. Full replication was ablated by various treatment doses. However,
evidence of viral immediate early proteins within the cells was never completely eliminated
indicating that some viral gene transcription was still occurring. In conclusion, UV-C may be
a safe alternative to pasteurisation for the treatment of human donor milk that preserves the
bioactivity. However, our data suggests that CMV inactivation will have to be carefully eval-
uated for each device designed to treat breast milk using UV-C irradiation.
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Introduction
Pasteurized donor human milk (PDHM) is an important alternative to artificial formula for
very preterm infants in an increasing number of neonatal intensive care units worldwide. Ide-
ally, PDHM is provided to very preterm infants whose mothers have difficulty establishing or
maintaining a breast milk supply. One of the most compelling justifications for providing
PDHM instead of commercial preterm infant formula is the associated reduction in necrotizing
enterocolitis (NEC), a devastating inflammatory bowel condition that is associated with
extreme prematurity and can lead to bowel perforation and rapid death [1].
Donor breast milk is generally processed by Holder pasteurization (heating at 62.5°C for
30 minutes), [2] and reliably produces a microbiologically safe product reducing bacterial
loads by 105 colony forming units per mL [3] and effectively inactivating cytomegalovirus
(CMV), a virus commonly present in breast milk that can cause severe infection in very pre-
term babies [4]. However, Holder pasteurization also reduces the concentration of immuno-
protective proteins such as lactoferrin, lysozyme and secretory IgA, potentially moderating
the beneficial effects of the breast milk [5]. Accordingly, other methods of processing breast
milk that will eliminate pathogens but preserve immune factors are being assessed. Recently,
Ultraviolet-C irradiation (UV-C, 254 nm) was shown to inactivate potential bacterial con-
taminants in breast milk (Staphylococcus epidermidis, Escherichia coli, Enterobacter cloacae,
Bacillus cereus, Staphylococcus aureus) and to preserve lactoferrin, lysozyme and secretory
IgA concentration [6,7].
While many microbial pathogens in breast milk are introduced inadvertently (e.g. skin or
gut flora introduced during breast pumping), CMV will inevitably be present in many milk
donations. In Australia, around 50–80% of women of fertile age are CMV seropositive prior to
pregnancy [8] and the majority will experience a focal reactivation of CMV in the mammary
glands with subsequent excretion of virus into breast milk for up to 2 months postpartum
[9,10]. Whilst term and moderately preterm babies are generally asymptomatic after post-par-
tum CMV infection, babies born at<28 weeks gestation are vulnerable to symptomatic infec-
tion leading to hepatitis and sepsis-like syndromes [11–13]. These babies are most likely to be
offered pasteurized donor human milk, and it is important that the inactivation of CMV by
UV-C is carefully validated if it is to be considered a suitable treatment for donor breast milk.
We confirm here that UV-C irradiation can effectively inactivate CMV in breast milk, but




Human foreskin fibroblasts (HFF) were kindly provided by Professor Jane Allan (UWA, Perth,
Australia). These were grown in Dulbecco’s Modified Enrichment Medium (DMEM), High
Glucose (GIBCO), supplemented with 8% newborn bovine serum (NBS) in 5% CO2 at 37°C
during subculture and in 2% NBS during viral titre evaluation.
Virus stocks
A cell culture—adapted strain of CMV, AD169 [14], was kindly supplied by Professor Jane
Allan (UWA, Perth, Australia) and was propagated in HFFs. High titre stock was generated by
centrifugation of virus-inoculated cells (950 x g) for 30 minutes. Stocks were quantified by Tis-
sue Culture Infectious Dose 50 analysis.
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Sample collection and ethics Statement
Frozen pasteurized breast milk was provided in 10 mL aliquots by the Hartmann Human Lac-
tation Research Group at the University of Western Australia. Aliquots from the same stock
were used for all viral inactivation studies. The use of human milk for this project was approved
by the Human Research Ethics Committee of the University of Western Australia (RA/4/1/
2369). All donors gave written consent for their donations to be used in research and the sam-
ples were de-identified prior to provision to our laboratory. Milk was processed by Holder pas-
teurization and stored in 10 mL aliquots in a -80°C freezer before use. Aliquots were thawed
immediately before use.
Tissue Culture Infectious Dose 50 (TCID50)
Virus stocks were diluted 10 fold in DMEM (Sigma-Aldrich, supplemented with 5% Pen/Strep
(Gibco, Life Technologies) and 2% newborn bovine serum in sterile 96 well trays. 100 μL virus
dilutions were inoculated onto confluent HFF cells that had been prepared in 96 well cell cul-
ture trays. Cells were incubated for 14 days (5% CO2, 37°C) and evaluated daily for the pres-
ence of cytopathic effect (CPE). Where characteristic cytomegalic CPE was identified, the well
was assigned as “+”. The number of positive wells per tray was entered into an online calculator
developed by Brett D. Lindenbach (Yale University) based on the protocol of Reed and Muench
[15] to provide a value of TCID50/mL. All samples showing no cytopathic effect were incubated
for 21 days and re-examined to ensure that there was no viral growth.
Ultraviolet-C irradiation
The UV light box apparatus was kindly provided by the Hartmann Human Lactation Research
Group (US Patent WO 2014094189, [16]). It consisted of a wooden box with a UV-C light
(254 nm) attached to the top surface with a metal slide situated immediately below the light,
which completely protected the sample from irradiation when closed. 180 μL (approximately
0.5 mm depth) breast milk inoculated with a ratio of 1:5 AD169 virus stock to pasteurized milk
() was placed in a machine drilled well on a sterile metal sample plate (0.4 mm depth). A mov-
able stage was used to select the appropriate distance from the light, which was measured from
the top of the slide (immediately below the UV-C light) to the top of the metal well on the mov-
able stage using a metal vernier caliper. The UV-C light was turned on for 15 minutes prior to
dose measurement or sample irradiation. To deliver the dose, the sample box was placed over
the prepared sample with the slide closed, the slide was opened for the appropriate amount of
time, and then was closed and the light box removed. The sample was immediately processed
by TCID50 or immediately frozen at -80°C and assessed by TCID50 as a batch to avoid delays in
processing.
UV-C dose measurement
The irradiation dose was measured using a Gigahertz-Optik xX911 meter with a UV-3718
detector head following the manufacturer’s methods (Gigahertz-Optik, Puchheim, Germany).
4°C and -20°C storage of breast milk
10 mL human milk was spiked with a ratio of 1:5 virus stock to pasteurized milk (x 104. 1 mL
aliquots were stored in microfuge tubes and were frozen at -20°C or stored at 4°C. At 24, 48, 72
hours, aliquots were removed, thawed (-20°C samples), diluted tenfold and assessed by TCID50
on previously prepared 96 well trays of confluent HFF cells. Where the same sample of infected
milk was repeatedly frozen and thawed, a 10 mL sample was prepared, and frozen in a 15 mL
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tube (Falcon1, Corning1). This was completely thawed prior to removing 1 mL which was
immediately analyzed by TCID50. The remaining sample was refrozen.
Immunofluorescent staining of infected cells with a commercial
monoclonal antibody
5 mL of human milk was infected with a ratio of 1:5 virus stock to pasteurized milk (). Aliquots
of this mixture were treated with UV-C light (Standard 10 second time, variable 1–5 cm dis-
tance or standard 5 cm distance, variable 10–50 seconds time), and were immediately infected
on confluent HFF cells on 24 well cell culture trays. Trays were centrifugally enhanced by
centrifuging at 2000 x g for 30 minutes (Sigma 4K13), and were then incubated for 7 days at
37°C, 5% CO2. Media was removed and monolayers were washed with Tris Buffered Saline for
5 minutes. Monolayers were fixed with 1:1 Methanol: Acetone for 10 minutes at room temper-
ature and blocked with 10% normal goat serum in TBS. Cells were washed, and incubated with
1:500 Alexa-Fluor™ 488—labelled MAB810X (Millipore) in TBS plus 10% goat serum for 30
minutes at 37°C. Cells were washed and ProLong1 Gold AntiFade mountant with DAPI stain
(ThermoFisher Scientific) was applied, under a coverslip and allowed to cure overnight. Cells
were evaluated using a TE2000-U fluorescent microscope (Nikon, Japan). To eliminate bias,
confluent microscope fields of view (10 x objective lens) were chosen on the basis of DAPI
staining and were photographed using a UV-2A filter block (all cells). The same field was then
immediately photographed using a B-2A block (for Alexa-Fluor™ 488 detection) to allow the
proportion of fluorescently staining cells to be enumerated. Cells from both fields were auto-
matically enumerated using ImageJ 1.48p software (NIH, USA) by either converting to a binary
image (UV) or colour threshold adjustment prior to binary image conversion (B-2A) to give
the percentage of infected cells (DAPI plus MAB810X double staining) per field. Particle sizes
were set as a pixel size from 200 to infinity. Uninfected cells were used as a negative control,
and cells infected with untreated AD169 were used as a positive control in each assay. 10 fields
of view were evaluated for the variable distance evaluation and 5 fields of view were evaluated
for the variable time evaluation.
Statistics
Results are presented as mean ± standard deviation. These were calculated using GraphPad
Prism 6 for Windows, Version 6.07, (GraphPad Software Inc.)
Results
Incubation at 4°C and -20°C does not ablate CMV viability
Breast milk samples were inoculated with 5.9 x 104 TCID50/ mL AD169, were stored at either
4°C or -20°C and were evaluated at daily intervals by TCID50. As frozen breastmilk can be
safely stored significantly longer in the freezer, one sample was stored at -20°C for 21 days (504
hours). One sample stored at—20°C was repeatedly refrozen after a sample was removed.
Results are presented in Fig 1 and demonstrate that viable virus was not completely inactivated
after prolonged storage in these conditions.
UV-C irradiation in milk is more effective than irradiation in media in
inactivating cytomegalovirus
Breast milk or DMEM culture media was inoculated with 1.56 x 105 TCID50/ mL AD169 and
was irradiated for 10 seconds at 254 nm at 1, 2, 3 and 4 cm from the UV light. Irradiated sam-
ples and positive (untreated) control samples were assessed by TCID50. UV-C irradiation for
Ultraviolet C Inactivation of Cytomegalovirus in Breast Milk
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10 seconds successfully inactivated cytomegalovirus in breast milk but minimal viability was
maintained where the virus was inoculated into media (Fig 2).
UV-C irradiation for 10 seconds successfully inactivates
cytomegalovirus in breastmilk
Breast milk inoculated with 2.2 x 103 TCID50/ mL AD169 was irradiated for 10 seconds at 254
nm at 1, 2, 3, 4 and 5 cm from the UV light. Irradiated samples and a positive (untreated) sam-
ple were assessed by TCID50 (Fig 3A). An identical aliquot was treated with the same irradia-
tion conditions and was incubated for 7 days prior to staining with MABX, which is specific for
a non-structural immediate early protein. Infected cells were enumerated and are presented as
the % infected cells: total cells (Fig 3B). The minimal effective UV-C dose was 53 mJ/cm2 (Fig
3C).
UV-C irradiation at 5 cm successfully inactivates cytomegalovirus in
breast milk
Breast milk inoculated with 3.1 x 103 TCID50/ mL AD169 was irradiated at 5 cm from the UV
light for 10, 20, 30, 40 and 50 seconds. Irradiated samples and a positive (untreated) sample
were assessed by TCID50 (Fig 3D). An identical aliquot was treated with the same irradiation
conditions and was incubated for 7 days prior to staining with MABX. Infected cells were enu-
merated and are presented as the % infected cells: total cells. Results are presented in Fig 3E. At
30 seconds exposure (85 mJ/cm2), 2% of cells were immunofluorescent. At 40 seconds expo-
sure (114 mJ/cm2), less than 1% cells were immunofluorescent. This result was not improved
by 50 seconds irradiation (143 mJ/cm2, Fig 3F inset). The UV dose was measured as previously
described (Fig 3G). Fig 4 shows an example of the typical staining achieved using DAPI and
MABX.
Fig 1. The effect of low temperatures on HCMV viability. Pasteurized breast milk was spiked with AD169 stock 1:5 and 0.5 mL
aliquots were prepared and either stored at 4°C or frozen at -20°C. After 24, 48, 72 and 96 hours at 4°C or -20°C, samples were
removed/thawed and analysed by TCID50 on human foreskin fibroblasts (HFF). One sample was stored at -20°C for 21 days (504
hours). The presence or absence of CPE was determined for each well and calculated using the Reed and Muench Calculator. Results
are presented as TCID50/mL. Superscripts (1–4) underneath multiple freeze/thaw samples designate the number of times the sample
was thawed.
doi:10.1371/journal.pone.0161116.g001
Ultraviolet C Inactivation of Cytomegalovirus in Breast Milk
PLOS ONE | DOI:10.1371/journal.pone.0161116 August 18, 2016 5 / 12
Discussion
UV-C irradiation (200–280 nm) is currently used extensively to eliminate microbial contami-
nation in the food industry. We are currently investigating the ability of 254 nm UV-C, which
has previously been shown to reduce bacterial viability while simultaneously retaining the bio-
logical activity of the milk [6,7], for its ability to inactivate cytomegalovirus.
Both optimal (1cm) and suboptimal (5cm) UV-C irradiation protocols were evaluated with
the latter demonstrating efficacy where prolonged irradiation was provided. Irradiation of
CMV infected breast milk with 64 mJ/cm2 UV-C was shown to eliminate replicative virus and
to reduce the detection of intracellular CMV protein to less than 1% of cells in culture.
Although no replication competence was demonstrated (defined by the absence of CPE, Fig
3A), residual intracellular viral proteins were detected using a monoclonal antibody. UV-C
irradiation is known to affect cell viability by inducing DNA damage such as cyclobutane
pyrimidine dimers that impede DNA replication [17]. MABX is specific for a non-structural
immediate early protein, and this can theoretically be transcribed without complete replication
and virion production occurring. Limited immediate early transcription in CMV latency has
previously been demonstrated in vitro in mouse lung tissue after infection with murine cyto-
megalovirus and no translation of early or late proteins was detected [18]. The residual cells
demonstrating fluorescent staining after prolonged irradiation (40 and 50 seconds, 140 and
180 mJ/cm2 respectively) may therefore not be indicative of future productive infection. Evi-
dence for this was provided by the prolonged incubation (up to three weeks) of identically
treated virus in 96 well trays (for TCID50) that did not produce plaques (AD169 is a cell
Fig 2. UV exposed AD169 spikedmilk andmedia. Pasteurized breast milk or MEM culture medium were spiked with AD169 culture
1:5. 150 μL samples were irradiated for 10 seconds at 1, 2, 3 or 4 cm from the UV light source (estimated UV intensity 400, 100, 25 and 4
W/cm2 respectively). The irradiated samples were inoculated on to human foreskin fibroblasts (HFF). The presence or absence of CPE
was determined for each well and calculated using the Reed and Muench Calculator. Results are presented as TCID50/mL. Breast milk
samples with values below the limit of detection are designated (*).
doi:10.1371/journal.pone.0161116.g002
Ultraviolet C Inactivation of Cytomegalovirus in Breast Milk
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culture-adapted virus and produces identifiable CPE within 7 days). To further evaluate repli-
cation competence, future studies will assess the transcription of late CMV genes after UV-C
treatment. This will be important as we cannot completely exclude the possibility that viral rep-
lication is occurring.
Some natural suppression of CMV replication is suggested by the differing effects of CMV
inoculated into media (less effective inactivation at all treatment distances) than pasteurized
breast milk (Fig 2). All virus detected was at the limit of detection, however the result was con-
sistent and demonstrates that cell culture media is not an appropriate substitute for breast milk
when evaluating UV-C irradiation. Interestingly, UV-C would be expected to penetrate culture
media with greater efficiency than the more opaque breast milk. One of the obstacles with
using this technology to treat liquids such as milk is the difficulty with radiation penetrance
(estimated to be 0.5mm), and new methodologies will need to be developed to allow larger vol-
umes of milk to be treated [19].
The ingestion of breast milk containing viable CMV can result in postpartum infection in
very preterm babies [9]. The severity of infection is varied and a detrimental effect on the long
term developmental outcomes for infected infants has not consistently been shown. Illustrating
the confusion surrounding this area, while some investigators have concluded that post-par-
tum CMV infection is a relatively mild and self-limiting infection with no obvious long term
sequelae [20], others have published case studies of infants that are severely affected by infec-
tion [12,21] and a recent multi-centre study demonstrated an association between postnatal
CMV infection and increased risk of bronchopulmonary dysplasia [22]. In 2010 an evaluation
of the current post-partum CMV infection literature concluded that no statements could be
justified that either endorsed or did not recommend treatment of breast milk where mothers
were excreting CMV [23]. Very few long term follow up studies have been carried out and are
hampered by small numbers of participants producing underpowered studies [24,25]. A recent
report describing intellectual impairment in adolescents suggests that long term sequelae are
measureable [26].
Many neonatal intensive care units currently freeze breast milk at -20°C for up to 3 days
prior to feeding to very preterm infants to reduce CMV titres. The efficacy of this treatment
has been controversial with some investigators showing a significant reduction in viral titre
and some showing little benefit (discussed in [27]) including a recent study that reported a ran-
domized trial of milk freezing that did not show a reduction in CMV infections [28]. We did
not find a reduction in CMV viability associated with storage at -20°C and saw little effect on
viability after 21 days (504 hours) storage. Whilst these experiments were carried out using the
cell culture-adapted strain of CMV, AD169, these data may illustrate the worst case scenario at
the peak of CMV excretion into breast milk (illustrated in [29]). Certainly, other investigators
have concluded that freezing breast milk does not ultimately protect susceptible infants from
infection [30]. It is possible that a low titre of CMV excreted into breast milk is inactivated by
Fig 3. UV-C inactivation of HCMV. A—C. UV-C exposure of spiked breast milk for 10 seconds from 1 to 5 cm from the UV
light source. Pasteurized breast milk was spiked with AD169 culture 1:5. The irradiated samples were diluted tenfold and
inoculated on to human HFF and the TCID50 calculated using the method described by Reed and Muench [15]. A. Results are
presented as TCID50/mL. Breast milk samples with values below the limit of detection are designated (*). B. Irradiated samples
were inoculated onto HFF, centrifugally enhanced and cells were analysed by immunofluorescence at 7 days post infection.
Results are presented as % infected cells.C: UV dose delivered. D—F. UV-C exposure of spiked breast milk at 5 cm from
the UV light source for different durations. D: Pasteurized breast milk was spiked with AD169 and samples were irradiated at
5 cm from the UV light source for 10 to 50 seconds. The irradiated samples were assessed by TCID50. Breast milk samples with
values below the limit of detection are designated (*). E. Irradiated samples were inoculated onto HFF, centrifugally enhanced
and cells were analysed by immunofluorescence at 7 days post infection. Results are presented as % immunofluorescently
labelled cells. * <1% of cells fluorescently labelled. F: Inset shows results for 30, 40 and 50 seconds exposure.G: UV dose
delivered. Where error bars are present, images showmean ± standard deviation.
doi:10.1371/journal.pone.0161116.g003
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Fig 4. CMV infected HFF cells stained using DAPI andMABX. A Uninfected HFF cells (DAPI), B: Uninfected cells
(MABX)C, D:Cells infected with AD169, no UV-C treatment, C: DAPI, D: MABX. E, F: Cells infected with AD169, 10
seconds UV-C treatment (5 cm), E. DAPI, F: MABX,G, H: Cells infected with AD169, 50 seconds UV-C treatment (5
cm) G: DAPI, H: MABX.
doi:10.1371/journal.pone.0161116.g004
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freezing, but that this effect is overwhelmed as more virus is excreted as lactation proceeds
[31]. Prior CMV infection should not be a contraindication for breast milk donation or for
breast feeding generally. However, the risk to the population being provided with donor breast
milk (generally very preterm infants<32 weeks gestational age) is significant, and this poten-
tial pathogen is eliminated by Holder pasteurization.
Reports of pathology associated with post-partum infection with CMV in infants born at
>28 weeks gestational age are relatively rare, and it is possible that severely symptomatic infec-
tions and adverse long term outcomes are sometimes diluted by age categories that are too
broad. As the survival of infants born at 23 to 25 weeks gestational age improves worldwide,
the long term sequelae of postpartum CMV infection may become more evident. Holder pas-
teurization of breast milk from CMV seropositive mothers is performed in some neonatal facil-
ities. However, a recent report stemming from a transition from pasteurization to providing
untreated expressed breast milk in an Austrian neonatal unit demonstrated a non-significant
reduction in NEC and an increase in CMV infections with no increase in mortality suggesting
that the benefits of routine Holder pasteurization for this population are minimal and may
even cause harm [32]. An alternative method of milk treatment that effectively inactivates
CMV and simultaneously maintains other immunoprotective elements may reduce infant dis-
ease in the neonatal intensive care unit.
UV-C treated human milk retains substantial bioactivity while effectively killing bacteria
and inactivating the replicative capacity of CMV in breast milk. Other potential pathogens that
are also excreted into breast milk such as Human Immunodeficiency Virus will need to be eval-
uated before this alternative treatment is approved for use in the context of a human milk
bank.
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